Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.

As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval to Guangzhou Hospital's application for the License. Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.

Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of the Company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, also announced on September 15, 2024 that Guangzhou Hospital had obtained the License. The Company previously announced the listing of Concord Healthcare's H shares on the HKSE on January 9, 2024.